Post-Marketing Requirement Study to Evaluate the Safety of Octaplas Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.
Phase of Trial: Phase IV
Latest Information Update: 09 Mar 2018
Price : $35 *
At a glance
- Drugs Plasma (Primary)
- Indications Haemorrhage
- Focus Adverse reactions
- Sponsors Octapharma
- 05 Mar 2018 Status changed from recruiting to discontinued.
- 12 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Dec 2019.
- 12 Aug 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2019.